Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
ROCKVILLE, Md., Feb. 18, 2016 -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report the financial results for the fourth quarter and full year of 2015 after 5:00 PM ET on Wednesday, March 2, 2016.
Jack Khattar, President and Chief Executive Officer, and Greg Patrick, Chief Financial Officer, will host a conference call to present the fourth quarter and full year 2015 results on Thursday, March 3, 2016 at 9:00 AM ET. Following the presentation, the call will be open for questions.
A live webcast will be available at www.supernus.com.
Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.
| Conference dial-in: | (877) 288-1043 | ||
| International dial-in: | (970) 315-0267 | ||
| Conference ID: | 47017444 | ||
| Conference Call Name: | Supernus Pharmaceuticals 4Q 2015 Earnings Conference Call | ||
Following the live call, a replay will be available on the Company's website under the 'Investors' section. The webcast will be available on the Company's website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of impulsive aggression in patients who are already being treated with standard ADHD medication. SPN-812 is being developed for treatment of ADHD.
CONTACTS: Jack A. Khattar, President and CEO Gregory S. Patrick, Vice President and CFO Supernus Pharmaceuticals, Inc. Tel: (301) 838-2591 or INVESTOR CONTACT: Peter Vozzo Westwicke Partners Office: (443) 213-0505 Mobile: (443) 377-4767 Email: [email protected]
